Publications by authors named "J P Olivier"
Emergence of Neuroendocrine Tumors in Patients Treated with Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol Oncol
January 2025
Background And Objective: It has been shown that androgen receptor pathway inhibitor (ARPIs) treatment for metastatic castration-resistant prostate cancer (mCRPC) improves overall survival rates, but ARPIs appear to be associated with a higher frequency of treatment-related neuroendocrine prostate cancer (t-NEPC). Our aim was to quantify the proportion of prostate adenocarcinoma cases that transition to t-NEPC following ARPI therapy.
Methods: We conducted a comprehensive search of the literature on t-NEPC using databases including MEDLINE and Scopus.
Background: Active surveillance (AS) is the recommended approach for managing Grade-Group1 (GG1) prostate cancer (PCa). Incorporating MRI at entry improve patient selection and outcomes.
Objective: To evaluate long-term oncological outcomes of patients receiving AS selected with MRI at entry.
Responsiveness is one of four health system goals alongside health outcomes, equity in financing and efficiency. Many studies examining responsiveness report a composite satisfaction index or proportions of patients describing satisfaction with dimensions of responsiveness. Consequently, responsiveness is predominantly based on collation of service users' feedback and could be termed service responsiveness.
View Article and Find Full Text PDFArticle Synopsis
- * A systematic review of recent literature (2022-2024) was undertaken to evaluate diagnostic and treatment methods, providing evidence-based recommendations.
- * Key recommendations include using MRI before biopsies, considering transperineal biopsies to lower infection risks, and active surveillance for low-risk tumors to enhance patient management.
Purpose Of This Document: The Oncology Committee of the French Urology Association is proposing updated recommendations for the management of recurrent and/or metastatic prostate cancer (PCa).
Methods: A systematic review of the literature from 2022 to 2024 was conducted by the CCAFU on the therapeutic management of recurrent PCa following local or metastatic treatment, assessing the references based on their level of evidence.
Results: Molecular imaging is the standard approach for assessing recurrence after local treatment and should not delay early salvage treatment.